伊立替康联合FP方案治疗晚期食管癌疗效分析(1)
 |
| 第1页 |
参见附件(1376KB，2页)。
【摘要】 目的 评价伊立替康联合FP方案(PIF)和顺铂联合氟尿嘧啶(PF)方案治疗晚期食管癌的疗效及毒副反应。方法 73例确诊晚期食管癌患者，随机分为两组，PF方案组36例， PIF方案组37。每21 d为1周期，每2周期评价疗效。结果 73例均可评价疗效，PIF方案组总有效率59.46%, PF案组总有效率46.67%，两组近期疗效比较，差异无统计学意义。PIF 方案组平均疾病进展时间 TTP 5.9个月，平均生存期 12.2个月；PF组平均疾病进展时间TTP 4.4个月,平均生存期 9.3个月。PIF方组一年生存率46.8%，亦明显高于PF方案组 37.5%。主要的毒副作用为恶心呕吐、骨髓抑制、腹泻。 腹泻发生率二组之间比较差异具有统计学意义(P<0.05)；其余二组之间比较差异均无统计学意义。两组病例均无化疗相关性死亡。结论 PIF方案疗效要优于PF方案，毒副反应临床上可以接受，不失为晚期食管癌患者的一种选择。
【关键词】 伊立替康；晚期食管癌；化疗
Clinical study of irinotecan in combination with PF in treatmeant of advanced esophageal cancer
ZHANG Jingwei,DUAN Dongmei,REN Zhonghai.
Department of Oncology, Nan Yang Central Hospital, HeNan 473000, China
【Abstract】 Objective To evaluate the efficacy and adverse events of irinotecan(CPT11)combined with PF in the treatmentof patients with advanced esophageal cancer. Methods A totalof 73 cases with advanced esophageal entered this trial.The patientswere randomly divided into trial group and control group, and 37 cases received chemotherapy of PIF regimen.36 cases received chemotherapy of PF regimen.Each patient received at least 2 cyclesof chemotherapy. Results The efficacy and adverse events were evaluated in all patients. The overall response ratewas 59.46% in the PIF group and 46.67% in the PF group, the difference between the two groups did not reach statistical significance(P>0.05). The median time to progression(TTP)was 5.9 months in the PIF group and 4.4 months in the PF group.Themedian survival time(MST)was 12.2 months in the IP group and 9.3 months in the PF group.The main adverse events included elosuppression, nausea, vomiting and diarrhea.A lone diarrheawith statistically significant difference detected(P<0.05). Conclusion For advanced esophageal cancerpatients, PIF treatment achieves better therapeutic effects than PF treatment. it is toxicity is tolerable, It is valuable for clinical practicing.
【Key words】 Irinotecan;Advanced esophageal cancer; Chemotherapy
食管癌是常见的恶性肿瘤之一，预后较差，50%的患者在诊断时已为晚期。近年来各国学者不断研究探讨其有效的治疗方法，以期望改善食管癌患者的生活质量和延长生存期。晚期食管癌是以化疗为主要手段的综合治疗，食管癌对化疗相对敏感，DDP+5FU 治疗食管癌疗效确切而稳定，是目前食管癌的标准治疗方案，有效率在50%左右，我科自2004年5月至2009年5月期间,将73例晚期食管癌患者随机分成两组,分别给予PDD+5Fu方案(以下简称PF)和伊立替康(CPT11)联合PDD+5Fu方案(以下简称PIF)进行化疗 ......
您现在查看是摘要介绍页，详见PDF附件(1376KB，2页)。